Stay updated on Bispecific Antibody MCLA-158 Clinical Trial
Sign up to get notified when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.

Latest updates to the Bispecific Antibody MCLA-158 Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6, indicating a minor update to the page’s implementation. This appears to be a behind-the-scenes maintenance update rather than a change to the study content shown on the page.SummaryDifference0.0%

- Check15 days agoChange DetectedAn NIH grant/contract identifier was added to the study's identifiers, linking the trial to U.S. NIH funding.SummaryDifference0.0%

- Check29 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5 on the page. This appears to be a minor metadata/patch update and does not change study data or user-facing content.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page adds details about new expansion cohorts and dosing (RP2D of 1500 mg every 2 weeks for single-agent MCLA-158) and outlines planned combination cohorts with pembrolizumab, FOLFIRI, and FOLFOX. It also updates recruitment sites, investigators, and contact information across many locations.SummaryDifference6%

- Check44 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4 on the page, signaling a minor update to the study details page. No substantive study data or user-visible content appears to be changed.SummaryDifference0.0%

- Check72 days agoChange Detected- Page revision updated from v3.6.0 to v3.6.3, indicating a new build/version of the page rather than a change to the study content. This is a metadata-level update visible on the page.SummaryDifference0.0%

Stay in the know with updates to Bispecific Antibody MCLA-158 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.